Compare Incyte Corporation (INCY) vs Xcel Energy Inc (XEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Xcel Energy Inc — how do they compare? Incyte Corporation trades at $117.98 (market cap $23.11B), while Xcel Energy Inc trades at $78.4 (market cap $49.11B). The key difference: Xcel Energy Inc is far larger — about 2.1× Incyte Corporation's market cap, and Xcel Energy Inc pays a 3.01% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | XEL | |
|---|---|---|
Market Cap | $23.11B | $49.11B |
Sector | Health | Utilities |
52-Week High | $118.52 | $83.91 |
52-Week Low | $67.38 | $71.14 |
Enterprise Value | $19.13B | $86.55B |
Dividend Yield | — | 3.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $115.66, down 1.36% on the day, with a bullish technical signal from moving averages and strong fundamental performance including a 25.02% net income margin for 2025. Recent positive news includes regulatory approvals for Opzelura in Europe and the acquisition of Vega Therapeutics, expanding its hematology portfolio. Revenue grew to $5.14 billion in 2025, with earnings beating expectations in two of the last three quarters.
The outlook remains positive given robust profitability, pipeline advancements, and a majority analyst buy rating, though risks include competitive pressures and reliance on key drug performance. The stock's current price is slightly above the consensus target of $112.78, suggesting near-term consolidation potential amid longer-term growth catalysts.
Xcel Energy (XEL) trades at $78.71, down 0.08% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported mixed quarterly earnings, beating Q1 2026 estimates but missing Q3 and Q4 2025. Revenue grew to $14.67 billion in 2025, with a net income margin of 14.14%. Recent news highlights a $60 billion capital plan through 2030 to support electrical demand growth from data centers and industrial expansion.
XEL presents a stable utility investment with a 62.96% analyst buy rating and a consensus price target of $93.86, implying 19% upside. Key opportunities include EPS growth projected at 9.6% annually through 2028, but risks involve regulatory pushback on rate increases and high debt levels with a debt-to-asset ratio of 41.64% in 2025. The stock's valuation at a P/E of 22.7 is reasonable for its growth outlook.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Xcel Energy Inc
Xcel Energy manages utilities serving 3.7 million electric customers and 2.1 million natural gas customers in eight states. Its utilities are Northern States Power, which serves customers in Minnesota, North Dakota, South Dakota, Wisconsin, and Michigan
Read more on XEL →
